---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-097091"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-08-14T20:05:42+00:00"
generated_at: "2026-08-14T20:12:23.664149+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis fully enrolls Phase 3 AD trial with 850 patients; Q2 net loss $0.40/share

## Summary
- Pivotal Phase 3 AD trial fully enrolled with 850 patients, exceeding original target of 760; topline symptomatic data expected Q1 2027.
- PD OLE study enrolled 266 of 500 patients; full enrollment projected Q4 2026; 26 US sites activated.
- Q2 2026 net loss $0.40/share vs $0.32 in Q2 2025; R&D spend $12.0M vs $5.2M YoY.
- Cash $18.7M at June 30, 2026 vs $19.5M at Dec 31, 2025; 42.6M shares outstanding.
- Cheng Fang, Ph.D. promoted to Chief Scientific Officer; AD OLE study to initiate October 2026.

## SEC filing metadata
- accession: 0001104659-26-097091
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-08-14T20:05:42+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/0001104659-26-097091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926097091/tm2623272d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-097091
- JSON: https://secwatch.observer/filing/0001104659-26-097091.json
- Plain text: https://secwatch.observer/filing/0001104659-26-097091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.